Photocure ASA: Ipsen releases 1Q 2015 sales report
Oslo, Norway, 29 April 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, refers to the first quarter 2015 report from Ipsen released today. Photocure has a strategic partnership with Ipsen for the commercialization of Hexvix® in Europe, excluding the Nordic region.
In the first quarter 2015, inventory reductions in first quarter 2014 and the foreign exchange rate development contributed to a revenue increase from Ipsen of 33%, compared to the first quarter 2014.
Photocure will release the first quarter 2015 interim report 6 May at 07.30 (CET). The report will be presented at Hotel Continental, Oslo, Norway, at 08.30 (CET).
For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000, E-mail: ed@photocure.no
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.